Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has announced the record date for e-voting and payment of dividend to shareholders. The register of members and share transfer books will be closed from September 23 to 29, 2026, for the annual general meeting scheduled on September 29, 2026. The cut-off date for determining shareholders entitled to receive the dispatch of notice of the 33rd annual general meeting is September 4, 2026.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has approved the appointment of Mr. David Yeow as an Additional Independent Director, reconstituted the Audit Committee, and scheduled its 33rd Annual General Meeting for September 29, 2026.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd's wholly owned subsidiary, Time Medical International Ventures (India) Private Ltd., launched the CLARION 64/128-Slice AI-Driven CT System in India at the India Health Expo 2026.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has announced that its step-down subsidiary, Time Medical Philippines, has been awarded a province-wide digital healthcare project for rollout across Catanduanes Province. The project combines Health Kiosks with the PhilHealth-accredited FlynnCare Clinic Management System (CMS) for dissemination. This marks an important milestone toward the digitalization of Universal Health Care in the Philippines.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, from Shankar Varadharajan & Others, indicating a significant acquisition of shares in the company.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 for Shankar Varadharajan & PACs, indicating a significant acquisition of shares in the company.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating that Mr. Shankar Varadharajan and FMV Holdings Pte Ltd have acquired a significant stake in the company, with Mr. Varadharajan increasing his holding to 11.80% and FMV Holdings Pte Ltd increasing its holding to 51.20%.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has allotted 454,210 equity shares to FMV Holdings Pte Ltd, a promoter entity, upon conversion of warrants at an issue price of Rs. 23.40 per share.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has allotted 2,05,05,909 equity shares to its warrant holders at an issue price of Rs. 23.40 per share, aggregating to Rs. 35,98,78,702.95. The allotment has been made for cash, upon the receipt of the remaining exercise price of Rs. 17.55 per warrant.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has approved its Q1 FY 2026-27 financial results, showing a loss of Rs. 350.41 lakhs. The company has also announced the resignation of two independent directors and the reconstitution of its audit and nomination committees. Additionally, the company has allotted 2.05 crore equity shares to promoters and non-promoters.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd announces the resignation of two independent directors, Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain, due to personal reasons and pre-occupation with other professional commitments.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net loss of INR 350.41 lakhs. The company has also approved the reconstitution of its audit committee and nomination and remuneration committee following the resignation of two independent directors. Additionally, the company has allotted 2,05,05,909 equity shares on a preferential basis to promoters and non-promoters.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011, regarding the acquisition of shares by Shankar Varadharajan and FMV Holdings Pte Ltd. The disclosure includes details of the acquisition, such as the number of shares acquired, the percentage of total share capital, and the mode of acquisition. The acquisition was made through a preferential allotment upon conversion of warrants.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations, regarding the utilization of funds raised through a preferential issue of shares and fully convertible share warrants.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has allotted 1,42,78,217 equity shares to warrant holders at Rs. 23.40 per share, with a premium of Rs. 22.40 per share, aggregating to Rs. 25,05,82,708.35.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has allotted 66,31,664 equity shares to its promoter and promoter group entities at an issue price of Rs. 23.40 per share, aggregating to Rs. 11,63,85,703.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011, from Shankar Varadharajan & PACs, indicating a significant acquisition of shares in the company.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has allotted 23,00,000 equity shares to its promoter, Mr. Shankar Varadharajan, upon exercising the option available with the Share Warrant Holder to convert convertible warrants. The allotment was made for cash at an issue price of Rs. 23.40/- per share, aggregating to Rs. 4,03,65,000/-.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has published a newspaper advertisement regarding a special window for re-lodging transfer requests for physical shares that were rejected, returned, or not attended due to deficiencies in documents or process.

Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve un-audited financial results for the quarter ended 30th June 2026.